Mineralys Therapeutics: CEO Jon Congleton sold 75,000 shares

What happened

• Jon Congleton, CEO, sold 75,000 shares on Sep 30, 2026. The filing reports a weighted-average price of $25.46 and total proceeds of $1,909,665. The transaction type is recorded as a sale (code S).

Key details

• Transaction date and price: Sep 30, 2026; weighted-average price $25.46; reported per-share range $25.0000 to $25.8201.
• Shares sold and value: 75,000 shares for $1,909,665.
• Shares owned after the transaction: the filing does not report shares owned after the transaction.
• Footnotes: (F1) transactions were effected pursuant to a Rule 10b5-1 trading plan adopted Dec 23, 2025; (F2) the reported price is a weighted-average and the reporting person will provide a breakdown of shares sold at each price in the stated range upon request.
• Filing and report dates: report period Sep 30, 2026; filing date Oct 2, 2026.

Why it may matter

• The sale was executed under a 10b5-1 trading plan. This was a market/private sale (code S), not an option exercise or a gift.
• This filing does not show why the insider traded or why the company acted.